Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Hepatology, Arizona Liver Health, Chandler, Arizona.
Transplant Proc. 2023 Nov;55(9):2134-2142. doi: 10.1016/j.transproceed.2023.08.020. Epub 2023 Sep 24.
The prevalence of nonalcoholic fatty liver disease (NASH) and cryptogenic cirrhosis (CC) is constantly increasing in adolescents and young adults (AYAs).
In a retrospective UNOS database evaluation, we analyzed postoperative outcomes of AYAs with nonalcoholic NASH/CC undergoing LT between January 1, 2003 and March 5, 2021. After exclusions, 85,970 LT recipients, 393 (47.1%) AYAs with NASH/CC and 441 (52.9%) AYAs with other metabolic conditions, were analyzed.
During the study period, the number of LTs performed for AYAs with NASH/CC increased from 4%-7% but decreased from 6.6%-5.3% compared to LTs performed for NASH/CC in all ages. In comparison to AYAs with other metabolic conditions, AYA LT recipients with NASH/CC had a higher prevalence of metabolic syndrome (MetS) components, including diabetes and increased body mass index (P < .0001 for both). Patient and graft survival in AYAs with NASH/CC were significantly lower in comparison to AYAs transplanted for other metabolic conditions (P < .0001) (Hazard Ratio = 1.93, P < .001). Patient survival in AYAs with NASH/CC was significantly better in comparison to older (40-65-year-old) patients with the same diagnosis (P = .01).
Our study found that the overall number of LTs in AYAs with NASH increased significantly, but to a lesser degree compared to the older population with the same diagnosis. Outcomes after LT in AYAs with NASH/CC were worse compared to LT for other metabolic conditions, but significantly better in comparison to older patients. The prevalence of LT for NASH/CC in AYAs is growing. MetS may contribute to worse outcomes in AYAs.
非酒精性脂肪性肝病(NASH)和隐源性肝硬化(CC)在青少年和年轻成年人(AYAs)中的患病率不断增加。
在一项回顾性 UNOS 数据库评估中,我们分析了 2003 年 1 月 1 日至 2021 年 3 月 5 日期间接受 LT 的非酒精性 NASH/CC 的 AYA 患者的术后结果。排除后,分析了 85970 例 LT 受者,其中 393 例(47.1%)为 NASH/CC 的 AYA,441 例(52.9%)为其他代谢疾病的 AYA。
在研究期间,接受 NASH/CC 的 AYA 的 LT 数量从 4%增加到 7%,但与所有年龄段的 NASH/CC 的 LT 相比,从 6.6%下降到 5.3%。与其他代谢疾病的 AYA 相比,NASH/CC 的 AYA LT 受者的代谢综合征(MetS)成分,包括糖尿病和体重指数增加的发生率更高(两者均<0.0001)。与其他代谢疾病相比,NASH/CC 的 AYA 患者和移植物的存活率显著降低(P<0.0001)(风险比=1.93,P<0.001)。与具有相同诊断的年龄较大(40-65 岁)患者相比,NASH/CC 的 AYA 患者的生存状况显著改善(P=0.01)。
我们的研究发现,NASH 的 AYA 的 LT 总数显著增加,但与具有相同诊断的年龄较大的患者相比,增加的程度较小。NASH/CC 的 AYA 患者接受 LT 后的结果比其他代谢疾病差,但与年龄较大的患者相比显著改善。NASH/CC 在 AYA 中的 LT 患病率正在增加。代谢综合征可能导致 AYA 的结果恶化。